Dresbuxelimab Biosimilar – Anti-CD73 mAb – Research Grade from ProteoGenix; catalogue PX-TA1754; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Dresbuxelimab Biosimilar, also known as Anti-CD73 mAb, is a research grade monoclonal antibody that has shown potential as a therapeutic agent in various diseases. This biosimilar is designed to target the CD73 protein, which plays a crucial role in regulating the immune response and promoting tumor growth. In this article, we will explore the structure, activity, and potential applications of Dresbuxelimab Biosimilar.
Dresbuxelimab Biosimilar is a humanized IgG1 monoclonal antibody that is produced using recombinant DNA technology. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a unique binding site that specifically recognizes the CD73 protein, making it a highly specific therapeutic agent.
The primary activity of Dresbuxelimab Biosimilar is its ability to bind to the CD73 protein and inhibit its function. CD73 is an ecto-enzyme that is expressed on the surface of various cells, including immune cells and tumor cells. It plays a critical role in the production of adenosine, a molecule that suppresses the immune response and promotes tumor growth. By binding to CD73, Dresbuxelimab Biosimilar prevents the production of adenosine, thus enhancing the immune response and inhibiting tumor growth.
In addition to its primary activity, Dresbuxelimab Biosimilar also has other potential activities. It has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which can lead to the destruction of CD73-expressing cells. This could be beneficial in the treatment of diseases such as cancer, where CD73 is overexpressed.
Dresbuxelimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various indications. Its primary application is in the treatment of cancer, particularly solid tumors. CD73 is known to be overexpressed in many types of cancer, and its inhibition by Dresbuxelimab Biosimilar can potentially slow down tumor growth and enhance the effectiveness of other cancer treatments.
In addition to cancer, Dresbuxelimab Biosimilar has also shown potential in the treatment of autoimmune diseases. CD73 is involved in the regulation of the immune response, and its inhibition by Dresbuxelimab Biosimilar can help in controlling the hyperactive immune response seen in autoimmune diseases. This biosimilar has also been studied in inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, with promising results.
In summary, Dresbuxelimab Biosimilar is a research grade monoclonal antibody that specifically targets the CD73 protein. Its primary activity is the inhibition of CD73, which can enhance the immune response and inhibit tumor growth. This biosimilar has potential applications in the treatment of cancer, autoimmune diseases, and inflammatory diseases. With ongoing clinical trials, Dresbuxelimab Biosimilar has the potential to become a promising therapeutic agent in the future.
ProteoGenix catalogue number PX-TA1754. For research use only.
Target: Dresbuxelimab Biosimilar – Anti-CD73 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Dresbuxelimab Biosimilar – Anti-CD73 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
